Open access

2 Nilogen oncosystems’s 3D-PREDICT tumoroid model is an ex vivo precision oncology and co-clinical trial enrichment platform
Seth Currlin, Angie Rivera, Michelle Ataya, Jasmin D’Andrea, Alliyah Humphrey, Jared Ehrhart, Rikhia Chakraborty, Soner Altoik

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A2; DOI: 10.1136/jitc-2023-SITC2023.0002
18 Generation and validation of humanized GARP/TGFB1 mice for testing novel anti-human GARP antibodies
Zhenlan Niu, Xiaofei Zhou, Ruili Lv, Jianing Li, Yuelei Shen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A20; DOI: 10.1136/jitc-2023-SITC2023.0018
19 Preclinical CD3-based mouse models for evaluation of bi-specific T-cell engager antibodies
Chengzhang Shang, Chong Li, Chang Liu, Jay Zhang, Yuelei Shen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A21; DOI: 10.1136/jitc-2023-SITC2023.0019
20 Evaluating the survival outcomes of an anti-isoAspELAVL4 response in a small cell lung cancer mouse model
Diego A Velarde, Joseph Valdes, Sarah Elmalh, Hannah Lee, Matthew Gladstone, Chunli Yan, Wijbe Kast, Ite Offringa

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A22; DOI: 10.1136/jitc-2023-SITC2023.0020
21 Increased mutation burden alone is not sufficient to increase immunogenicity of DNA mismatch repair deficient tumors
Peter MK Westcott, Francesc Muyas, Haley Hauck, Olivia C Smith, Nathan Sacks, Zack Ely, Alex M Jaeger, William Rideout, Daniel D Zhang, Arjun Bhutkar, Mary Clare Beytagh, David Canner, Roderick Bronson, Santiago Naranjo, Abbey Jin, Justin Patten, Amanda M Cruz, Sean-Luc Shanahan, Isidro Cortes-Ciriano, Tyler Jacks

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A23; DOI: 10.1136/jitc-2023-SITC2023.0021
22 Humanized NOG-EXL mice exhibit improved overall survival and less severe myeloid cell activation relative to humanized NSG-SGM3 mice
Elinor Willis, Jillian Verrelle, Esha Banerjee, Charles-Antoine Assenmacher, James C Tarrant, Nicolas Skuli, Moriah L Jacobson, Zev Binder, Enrico Radaelli

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A24; DOI: 10.1136/jitc-2023-SITC2023.0022
23 Expression of Ras and Rab interactor 1 (Rin1) and Notch1 in head and neck tumours at selected hospitals in Ghana
Roland Osei Saahene, Francis Agyemang Yeboah, Precious Barnes

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A25; DOI: 10.1136/jitc-2023-SITC2023.0023
24 Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain
Rebecca Cottman, Vanessa Johnson, Michelle Hung, Yin Yin Chong, Eren Chu, Assen Roguev, Marcus Gainer, Joseph Sperling, Monika Avina, Brett Kiedaisch, Raghav Kannan, Chandra Verma, Chew-Li Soh, Conor McAuliffe, Mark Tomishima, Russell M Gordley, Timothy K Lu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A26; DOI: 10.1136/jitc-2023-SITC2023.0024
25 Establishment of tumor-on-chip system to study the role of tumor microenvironment on cancer progression in a patient-specific manner
Samaneh Kamali, Mara Gilardi, Abhay Andar, Karin Abarca Heidemann, Michael Ritchie, Maria Mancini

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A27; DOI: 10.1136/jitc-2023-SITC2023.0025
26 Enhancing the anti-tumor efficacy of bispecific T-cell engagers via sialidase fusion
Peng Wu, Zhuo Yang, Yingqin Hou

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A28; DOI: 10.1136/jitc-2023-SITC2023.0026

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages